Q2 EPS Estimates for Haemonetics Boosted by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Equities researchers at Zacks Research increased their Q2 2028 EPS estimates for Haemonetics in a research report issued to clients and investors on Tuesday, March 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $1.47 for the quarter, up from their prior estimate of $1.46. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

Several other equities research analysts have also issued reports on HAE. JPMorgan Chase & Co. lifted their price objective on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. BTIG Research restated a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Barrington Research set a $94.00 price target on Haemonetics in a report on Friday, February 6th. Finally, Needham & Company LLC downgraded Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Stock Down 2.8%

HAE opened at $53.96 on Friday. The firm has a market capitalization of $2.51 billion, a P/E ratio of 14.86, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28. Haemonetics has a one year low of $47.31 and a one year high of $87.32. The company has a fifty day moving average price of $62.27 and a 200-day moving average price of $64.97. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the prior year, the firm posted $1.19 EPS. Haemonetics’s revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HAE. AQR Capital Management LLC raised its position in Haemonetics by 48.6% during the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after purchasing an additional 1,034,226 shares in the last quarter. River Road Asset Management LLC increased its position in shares of Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after purchasing an additional 260,624 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Haemonetics by 994.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after purchasing an additional 1,254,035 shares during the last quarter. North Peak Capital Management LLC raised its holdings in shares of Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after buying an additional 740,626 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Haemonetics by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after buying an additional 26,763 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.